ArticleScientific reports2025
Supercell-enhanced multimodal plasmonic sensor for high-fidelity antigen detection via refractive index modulation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Innovations in Biosensing Technologies for Cancer Diagnosis and Theranostics.Mini reviews in medicinal chemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we investigate a multispectral plasmonic refractive index sensor based on a ring resonator supercell array for the detection of carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), and hemoglobin (Hb). The sensor exhibits three resonance modes within the 1000-3000 nm wavelength range, analyzed using the finite-difference time-domain (FDTD) method. Through meticulous optimization of the sensor's geometrical structure, we achieve a high figure of merit (FOM) and sensitivity. Notably, the second resonance mode attains the highest sensitivity of 913.51 nm/RIU. Furthermore, the third resonance mode achieves an FOM exceeding 70 RIU
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.